UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 17, 2015

TherapeuticsMD, Inc.
(Exact Name of Registrant as Specified in its Charter)

Nevada	**001-00100**	**87-0233535**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6800 Broken Sound Parkway NW, Third Floor
Boca Raton, FL 33487
(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (561) 961-1900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2 below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

TherapeuticsMD, Inc. is furnishing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation which will be used, in whole or in part, and subject to modification, on August 17, 2015 and at subsequent meetings with investors or analysts.

The information in this Current Report on Form 8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor will any of such information or exhibits be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) *Exhibits.*

Exhibit Number	Description
99.1	TherapeuticsMD, Inc. presentation dated August 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 17, 2015

THERAPEUTICSMD, INC.

By: /s/ *Daniel A. Cartwright*
Name: Daniel A. Cartwright
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	TherapeuticsMD, Inc. presentation dated August 2015.

Exhibit 99.1


TherapeuticsMD®
A Woman's Health Company
TXMD Overview
August 2015
www.TherapeuticsMD.com
THER-0061 V3 8/15

Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop, protect and defend our intellectual property; our ability to develop and commercialize our hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of our clinical trials; potential adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock; and the concentration of power in our stock ownership.

PDF copies of press releases and financial tables can be viewed and downloaded at our website: **http://www.therapeuticsmd.com/pressreleases.aspx.**

TherapeuticsMD (TXMD)

Innovative women's health company exclusively focused on developing and commercializing products for women throughout their life cycles

Drug candidate portfolio is built on patented SYMBODA™ technology, developed to enable new bio-identical hormone combinations, forms and administration routes

Pipeline Targets Large Markets



1) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.
2) Pinkerton, J.V. 2015. *Menopause, Vol 22, No.9, pp 9-11.*
3)) Estimated U.S. sales, based on half estradiol patch sales.
* In July 2014 we temporarily suspended enrollment in the Spry Trial and, in October we temporarily stopped it in order to update the Phase 3 protocol based on discussions with the FDA. We intend to update the Phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial.

TherapeuticsMD®

Key Milestones



TX-004HR
VVA Program

TherapeuticsMD®

Overview – Vulvar and Vaginal Atrophy (VVA)

- Diagnosed in approximately 50% of postmenopausal women[1]
- Most bothersome symptom commonly reported is dyspareunia[1]
- FDA guidance for efficacy requirements:
  - Statistically significant increase in superficial cells
  - Statistically significant decrease in parabasal cells
  - Statistically significant change in vaginal pH
  - Statistically significant reduction in severity of dyspareunia

Healthy Vaginal Tissue

Superficial cells: >15%

Intermediate cells: 80%

Parabasal cells: < 5%

Atrophic Vaginal Tissue

<5%

60%

>30%



1) Kingsberg, Sheryl A., et al. "Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings from the REVIVE (REal Women's Views of Treatment Options for Menopausal Vaginal ChangEs) Survey." International Society for Sexual Medicine 2013, no. 10, 1790-1799.

VVA Market – Established and Growing

- U.S. sales more than doubled since 2008
- Global market expected to be $2.1 billion in 2022[4]
- Currently no generic competition
- 32 million U.S. women currently experiencing VVA symptoms

Product[2]	Compound	TRx[1] 12 Month Rolling (000)	U.S. Sales ($MM)[1] 12 Month Rolling	WAC Price[3]
Premarin® Cream	Equine vaginal estrogen	1,774	$511	$263.52
Vagifem® Tablets	Vaginal estradiol	1,851	$463	$306.00*
Estrace® Cream	Vaginal estradiol	1,751	$406	$240.05
Osphena® Tablets	Oral SERM	280	$67	$158.00
Estring®	Vaginal estradiol ring	336	$99	$283.66
Total		**5,992**	**$1,546**	

1) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.
2) Femring data is excluded due to VMS indication.
3) Medi-Span Price Rx Basic as of 6/10/15. * for 18 tablets ($136.00 WAC for 8 tablets)
4) GlobalData July 2013 report GDHC54PIDR.

TherapeuticsMD®

VVA Market Dynamics – Ready for New Product

Only 2.3MM U.S. women treated with Rx product[1]

Why?

Creams

- Messiness[2]
- Long-term safety[2]
- Dose preparation by user required[3]

→ Mean treatment duration **46 days**[4]

Tablets

- Long-term safety[2]
- Systemic absorption[2]

→ Mean treatment duration **103 days**[4]

→ Women primed for conversion to new product

1) IMS Health Plan Claims (April 2008-Mar 2011).
2) Wysocki, S et al. Management of Vaginal Atrophy: Implications from the REVIVE Survey. *Clinical Medicine Insights: Reproductive Health* 2014:8 23-30 doi:10.4137/CMRH.S14498.
3) The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902.
4) Portman, D, et al. One Year Treatment Persistence with Local Estrogen Therapy in Postmenopausal Women Diagnosed as Having Vaginal Atrophy. *Menopause: The Journal of The North American Menopause Society* Vol. 22, No. 11, Published online ahead of print May 4, 2015.

TherapeuticsMD®

30MM Women with VVA Untreated in U.S.**



1) The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902.
2) Gass ML, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women's Health Initiative. Menopause. 2011;18(11):1160–1171.
3) IMS Health Plan Claims (April 2008-Mar 2011).

** Not treated with an FDA approved Rx product. OTC products do not effectively treat the underlying pathological causes of VVA and therefore do not halt or reverse the progression of this condition.

TherapeuticsMD®

Vagifem® 25 mcg to 10 mcg Market Share

	Vagifem	
Year	**2009**	**2014**
Dosage Strength	**25 mcg***	**10 mcg***
Market Share[1] (%)	**40%**	**32%**

- VVA market TRx increased 15% 2009-2014[1]
- Vagifem had an 18% decrease of its own market share moving to 10 mcg only

1) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, Annual Data 2009-2014.
*Vagifem 25 mcg was discontinued on July 30, 2010. Vagifem 10 mcg was approved by the FDA November 25, 2009 and began shipping to pharmacies in Q1 2010.

TherapeuticsMD®

TX-004HR – Target Product Profile

Target Goals	Preliminary Supportive Data
Lower systemic exposure	Phase 1 data with 10 mcg and 25 mcg suggest lower systemic absorption
Faster onset of action	Phase 2 demonstrated efficacy in 14 days
New lower effective dose	Phase 3 evaluating broad range of doses, including 4, 10 and 25 mcg
Improved user experience	Phase 2 showed patient satisfaction; 97% said “easy to use”

Target Product Profile being evaluated in ongoing Phase 3 Rejoice Trial

TX-004HR Vaginal Estradiol U.S. Launch Timeline



- **Phase 3 Trial[1]: 12 weeks, ~100 sites**
- **Subjects: ~700 fully enrolled as of June 2015**
  - 3 active arms: 4 mcg, 10 mcg, 25 mcg (~175 per arm)
  - 175 placebo
- **FDA required Co-Primary Endpoints for Proposed Indication**
  (from baseline to week 12 versus placebo)[2,3]
  - Statistically significant increase in the % of vaginal superficial cells
  - Statistically significant decrease in the % of vaginal parabasal cells
  - Statistically significant change in vaginal pH
  - Statistically significant reduction in the severity of dyspareunia
- **Additional Endpoints**
  - PK measures Days 1,14, 84
  - FSFI (Female Sexual Function Index), acceptability survey

1) NCT02253173. https://clinicaltrials.gov/ct2/show/NCT02253173?term=rejoice&rank=1.
2) Each arm (4 mcg, 10 mcg, and 25 mcg) tested against each co-primary endpoint.
3) The FDA has noted that a single, large, well-controlled clinical trial to support safety and efficacy should be sufficient to submit an NDA for TX-004HR for the proposed indication and that to support the indication in a single trial, evidence of efficacy for a given dose would need to show statistical significance of at least a .01 level.

TX-004HR Phase 3 Trial Timelines & Milestones



Last Subject Last Visit Details*

- Last subject last visit scheduled for Sept 2015
- Endometrial biopsy (EB) – 3 independent pathologists must read
- If insufficient tissue, repeat EB
- If insufficient tissue on repeat biopsy – transvaginal ultrasound (TVU) assessment
- If endometrium >4 mm on TVU, then hysteroscopy guided biopsy with specimens sent to all three pathologists

** A telephone interview is conducted at Week 14 (15 days after the last dose of investigational product as per study protocol).

TX-004HR Phase 2 Study
Double-blind and Placebo-controlled

Study Design

- 48 postmenopausal women with VVA (24 active, 24 placebo)
- Randomized 1:1 to 10 mcg; 1x daily for 2-week period
- Endpoints measured at 2 weeks; same endpoints to be measured in Phase 3 at 12 weeks

Co-primary Endpoint Results[1]

- Increase in superficial cells 35% treatment vs. 4% placebo (*P*=0.0002)
- Decrease in parabasal cells 54% treatment vs. 4% placebo (*P*<0.0001)
- Decrease in vaginal pH -0.97 units for treatment vs. -0.34 units for placebo (*P*=0.0002)
- Numerical reduction of most bothersome symptoms

Secondary Endpoint Results

- Improved patient satisfaction, 97% said easy to use[2]
- Reduction in atrophic effects on epithelial integrity and vaginal secretions[3]

1) Pickar, J.H. et al, Pilot and Pharmacokinetic Studies of Solubilized Estradiol Administered Vaginally in a Softgel Capsule. *Menopause*. 2014; Vol.23, No.12, S-6, 1328.
2) Kingsberg, Sheryl "Patient Experience with Solubilized Estradiol Given Vaginally in a Novel Softgel Capsule (VagiCap™) presented 2015 Annual Meeting ISSWSH, Feb 20, 2015.
3) Constantine, G.D., "Vaginal Physical Examination Correlates with Vaginal Epithelial Cells and pH and Can Be Used to Assess Therapeutic Efficacy," FRI-126. ENDO2015.org, Endocrine Society Meeting and Expo Guide, p. 229.

TX-004HR vs. Vagifem®
Phase 1 Single Dose PK Studies

Key Findings

- Tmax ~2 hours with TX-004HR and ~8 hours with Vagifem
- Systemic absorption AUC (0-24 hours) is 2- to 3-fold lower with TX-004HR relative to Vagifem





TX-001HR
Combination Program

TherapeuticsMD®

Menopause Overview

Menopause represents the natural life-stage transition when women stop having periods and may result in physical and emotional symptoms.

- Average age of menopause is 51 years[1]
- Hot flashes are due to lower estrogen levels
- Estrogen is given to reduce hot flashes
- Estrogen causes the uterus to thicken (hyperplasia)
- Progesterone is given to non-hysterectomized women to prevent thickening of the uterus

1) National Institutes of Health, National Institute on Aging, https://www.nia.nih.gov/health/publication/menopause.

FDA Approved Hormone Therapy Market Size

FDA-Approved Product		U.S. Sales ($MM)[1]	Company
17β Estradiol + NETA / DSP Activella® / FemHRT® / Angeliq®	**Non bio-identical containing progestins**	**$37**	Warner Chilcott, Bayer, novo nordisk®
Generic 17β + Progestins	**Non bio-identical containing progestins**	**$230**	TEVA Pharmaceuticals
Premarin + MPA Prempro® / Premphase®	**Non bio-identical CEE + progestin**	**$339**	Pfizer
Premarin + SERM Duavee®	**Non bio-identical CEE + SERM**	**$19**	Pfizer
Paroxetine Brisdelle®	**SSRI non-hormonal**	**$36**	noven PHARMACEUTICALS, INC.
Total FDA-Approved Oral Combination Sales		**$661**	

1) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.

Hormone Therapy Market = Two Markets

Total Combination E+P Market

$2.2 billion =



1) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.
2) Pinkerton, J.V. 2015. *Menopause, Vol.22, No.9, pp 0-11.*

Number of U.S. Women Using **Non-FDA-Approved** Compounded HT

Pinkerton, J.V. Compounded bio-identical hormone therapy: identifying use trends and knowledge gaps among U.S. women. *Menopause* Vol.22, No.9, 2015.

Pinkerton, J.V. Menopause Hormone Therapy (MHT) Usage: FDA-Approved MHT has decreased while Compounded non-FDA-approved MHT has increased, ENDO, 2015.

Archer, D.F., et al. Prevalence of Use and Cost of Compounded Menopausal Hormone Therapy (CMHT) 2015 ACOG, presentation, May, 2015.

1-2.5MM U.S. women using custom-compounded menopausal hormone therapy

30MM* Annual custom-compounded prescriptions

$49 Average monthly cash cost

* The reported number of annual custom compounded hormone therapy prescriptions is estimated at 26MM to 33MM.

Evidence Supports Bio-identical Progesterone

Favorable Clinical Profile Compared to Synthetic Progestins



Bio-identical Progesterone	Synthetic Progestins	References
Favorable CNS profile	No benefit on sleep properties	Freeman E, et al[1]
Favorable breast profile	Increased risk of breast cancer	E3N-EPIC[2]
Favorable cardiovascular profile	Increased risk of MI, stroke, VTE	PEPI[3], ELITE[5]
Favorable lipid profile	Less favorable lipid profile effects (cholesterol, LDL, trigycerides)	PEPI[3]
Adequate endometrial protection	Adequate endometrial protection	PEPI[4]
Low incidence of bleeding	High incidence of bleeding	Lorrain, et al.[6]

1) Freeman E, Rickels K, Sondheimer S J. et al. A double-blind trial of oral progesterone, alprazolam and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274:51–57.
2) Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103–111.
3) Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin regimes on heart disease. Risks factors in postmenopausal women. JAMA. 1995;273:199–208.
4) The Writing Group for the PEPI Trial . Effects of hormone replacement therapy on endometrial histology in postmenopausal woman. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;275:370–375.
5) Hodis HN, et al "Testing the menopausal hormone therapy timing hypothesis: The early versus late intervention trial with estradiol" AHA 2014; Abstract 13283.
6) Lorrain J, Lalumiere L G, Caron P. The effects of oral micronized progesterone on bleeding patterns, endometrial histology and bone density in postmenopausal women on hormone replacement therapy. Int J Gynaecol Obstet. 1994;46:77–79.

TherapeuticsMD®

Evidence Supports Bio-identical Estradiol

Favorable Clinical Profile Compared to Conjugated Estrogens

"CEEs (Premarin) were associated with a higher incidence of venous thrombosis and myocardial infarction than estradiol."[1]

— *Journal of the American Medical Association,* September 2013

"Oral estradiol may be associated with a lower risk of stroke … compared with conventional-dose oral CEE."[2]

— *Menopause,* September 2014

The ELITE trial demonstrated that estradiol is cardioprotective when given during the early postmenopausal years.[3]

— *Circulation,* November 2014

Cochrane meta analysis demonstrated that estradiol is cardioprotective and reduced overall mortality when given 10 years before the onset of menopause.[4]

— Cochrane Collaboration, 2015

1) Smith *et al.* Lower Risk of Cardiovascular Events in Postmenopausal Women Taking Oral Estradiol Compared with Oral Conjugated Equine Estrogens (CEE).
2) Shufelt *et al.* Hormone Therapy Dose, Formulation, Route of Delivery, and Risk of Cardiovascular Events in Women: Findings from the Women's Health Initiative Observational Study.
3) Abstract 13283: Testing the Menopausal Hormone Therapy Timing Hypothesis: The Early versus Late Intervention Trial with Estradiol ;HN Hodis, et al.1 Circulation. 2014; 130:A13283.
4) Cochrane Collaboration; HT for preventing cardiovascular disease in postmenopausal women; Boardmen HMP, et al., 2015.

Medical Societies Express Concern Over Compounded Hormones

- ACOG and ASRM Committee Opinion states compounded hormones may pose additional risks compared to FDA approved products[1]
  - Lack of Good Manufacturing Practices (GMP)
  - Variable purity
  - Variable content uniformity
  - Variable potency (under/over dose)
  - Not approved for efficacy and safety
  - Lack of stability data
- Medical societies' global consensus statement declares that the use of custom-compounded hormone therapy is not recommended[2]

1) Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee, Number 532, August 2012 (Reaffirmed 2014, Replaces No. 387, November 2007 and No. 322, November 2005).
2) Villiers, T.J. et. al., Global Consensus Statement on Menopausal Hormone Therapy, *Climacteric*, June 2013, Vol. 16, No. 3 : Pages 316-337.

Compounding Regulations and Enforcement

Drug Quality and Security Act (DQSA)[1]

- Prohibits compounding of essential copies of an FDA-approved drug except in limited circumstances such as drug shortages
- Anticipate significant impact on compounding upon FDA-approval of first combination hormone therapy product



USP 800 – Hazardous Drugs[2,3]

- New identification requirements for receipt, storage, mixing, preparing, compounding, dispensing, and administration of hazardous drugs
- Considered “prohibitively expensive” requiring major pharmacy upgrades and renovations to be compliant

1) http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm376829.htm
2) http://www.usp.org/sites/default/files/usp_pdf/EN/m7808.pdf
3) https://www.ascp.com/sites/default/files/Joint%20USP%20letter%202015%20FINAL.pdf

TX-001HR – Target Product Profile

Target Goals	Preliminary Supportive Data
Meet patient demand for bio-identical hormones	Potential for FDA-approved first natural estradiol plus natural progesterone combination softgel
New lower effective dose	Broad range of doses being evaluated in Phase 3
Labeling differentiation	Bio-identical terminology as both hormones similar to those produced by the ovary
Leverage data on natural progesterone and 17β estradiol	Inclusion of progesterone/estradiol differences data via label negotiation

Target Product Profile being evaluated in ongoing Phase 3 Replenish Trial

TX-001HR Estradiol + Progesterone U.S. Launch Timeline



- Phase 3 Replenish Trial to enroll 1,750 subjects at ~100 U.S. sites
  - Four active arms (N=400/arm)
    - Estradiol 1 mg/Progesterone 100 mg
    - Estradiol 0.5 mg/Progesterone 100 mg
    - Estradiol 0.5 mg/Progesterone 50 mg
    - Estradiol 0.25 mg/Progesterone 50 mg
  - Placebo arm (N=150)
- 12-month study with 12-week VMS substudy endpoints:
  - Vasomotor substudy: number and severity of hot flashes (4 weeks and 12 weeks)
  - Endometrial safety: incidence of endometrial hyperplasia (12 months)

Replenish TRIAL

https://clinicaltrials.gov/ct2/show/NCT01942668?term=replenish+trial&rank=1

Early Stage Pipeline: Transdermal Programs

TherapeuticsMD®

Why Transdermal?

- Transdermal delivery perceived safer due to a lower first-pass effect
- No FDA-approved transdermal progesterone
- New TXMD PK data suggest leveraging solubilized progesterone, show elevated and sustained transdermal levels
- Leveraging this technology creates an opportunity for new progesterone IP, products and novel dosage forms

E+P Topical PK Results

New Formulation PK Data Suggest Sustained 8-hour Duration[1]





- Levels in the saliva and capillary samples are higher than in the serum, where it was not detectable[1]
- Consistent with published article from Du and Stanczyk 2013[2]

1) Data on File, TherapeuticsMD.
2) Du, Joanna Y. et al; *Menopause*, 2013, Vol 20, No.11, pp 1-7.

Proof Of Concept Efficacy Study[1]



Progesterone Levels



Uterine Weights



Mean ± SEM; n=8
* p=0.02 vs. Placebo Cream

Luminal Epithelial Cell Height



Mean ± SEM; n=8
**** p<0.0001 vs. Placebo Cream

1) Data on File, TherapeuticsMD.

* An ovarectomized rat (OVX) is a female rat whose ovaries have been removed.

31

TherapeuticsMD®

Transdermal Market Opportunity

Product (Combination E+P)	TRx[1] (000)	U.S. Sales ($MM)[1]	Company
Estradiol/Levonorgestrel (Climara Pro®)	111	**$23**	BAYER
Estradiol/Norethindrone Acet (CombiPatch®)	383	**$58**	noven PHARMACEUTICALS, INC.
Total Combination Transdermal Sales	**494**	**$81**	

Product (Estradiol Only)	TRx[1] (000)	U.S. Sales ($MM)[1]	Company
Estradiol (Patch, Gel, Spray) (Alora®, Climara®, Estraderm®, Menostar®, Vivelle®, Vivelle-Dot®, Minivelle®; Divigel®, Elestrin®, Estrogel®; Evamist®)	5,674	**$814**	NOVARTIS, Allergan, MEDA, BAYER, ASCEND THERAPEUTICS, Lumara Health™, UPSHER-SMITH
Total Estradiol Transdermal Sales	**5,674**	**$814**	

1) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.

Intellectual Property Update

TherapeuticsMD®

Growing Patent Portfolio

	Filed	Provisional	Non-Provisional	Issued
U.S.	**48**	15	22	11
Ex-U.S.	**61**			

- Seven new patents issued in 2015 strengthening competitive barriers to entry and building on layered coverage strategies
- Others issued:
  - Field spanning estradiol and progesterone pharmaceutical compositions and methods
  - OPERA reporting and analysis software patent
- Layered patent strategies
  - Field spanning pharmaceutical compositions and methods by family of estradiol and progesterone alone and in combination
  - Siloed strategy for each product

Worldwide Patent Filings*

Strong IP Portfolio with 61 Patents Pending in 12 Jurisdictions Outside the United States



*Not all patent filings filed in all jurisdictions.

Investment Rationale

Investment Rationale

- **Worldwide commercial rights for multiple hormone therapy products in Phase 3** and earlier stages:
  - Well-known chemical entities with established safety and efficacy thresholds; 505(b)(2)
  - Unique, large, and growing markets with favorable competitive dynamics (DQSA)
  - Additional early stage pipeline candidates
  - Strong foreign IP portfolio with 61 patent applications pending in 12 foreign jurisdictions
- **Growing U.S. commercial business** marketing prescription and OTC prenatal vitamins
  - Customer base of OB/GYNs and other women's health specialists
  - Recognized by Deloitte Technology Fast 500 as 41st in North America
- **Experienced management team** with proven development and commercial success in women's health

TXMD: Financial Snapshot

Listing Exchange	NYSE MKT
Shares outstanding	177.5 million (as of August 3, 2015)
Cash	$67.2 million (as of June 30, 2015)
Financing net proceeds	$32.2 million (offering July 10, 2015)
Debt	$ 0 million


Thank You!
TherapeuticsMD®
www.TherapeuticsMD.com

Appendix

Long-Term Growth Opportunity



TX-004HR Phase 2 Study
Patient Experience Secondary Endpoint

Patient Experience Survey Results Summary[1]

- 97% reported “easy to use”
- 96% reported the TX-004HR softgel (VagiCap™) was “easy to insert”
- 94% reported “convenient to use”
- 0% experienced expulsion of capsule
- >60% “very satisfied”; 8% were “dissatisfied”
- 63% reported quality of life was “somewhat better” to “much better” after only 14 days of use

The satisfaction and quality of life questions were not defined and therefor open to patient interpretation

1) Kingsberg, Sheryl."Patient Experience with Solubilized Estradiol Given Vaginally in a Novel Softgel Capsule (VagiCap™) presented 2015 Annual Meeting ISSWSH, Feb 20, 2015.